Observational Prospective study to esTIMAte the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins –follow-up (OPTIMA II)

References

• World Health Organization. Fact Sheet 317: Cardiovascular diseases (CVDs). 2015. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/[Last accessed 18 February 2016]
   Google Scholar
• Nichols M, Townsend N, Scarborough P, Rayner M. European cardiovascular disease statistics. 2012. Available at: http://www.ehnheart.org/component/downloads/downloads/1436.html [Last accessed 18 February 2016]
   Google Scholar
• Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-8
   PubMed Web of Science ®Google Scholar
• Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-6
   PubMed Web of Science ®Google Scholar
• Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6
   PubMed Web of Science ®Google Scholar
• Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-3
   PubMed Web of Science ®Google Scholar
• Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8
   PubMed Web of Science ®Google Scholar
• Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8
   PubMed Web of Science ®Google Scholar
• Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006;48:1560-6
   PubMed Web of Science ®Google Scholar
• Kuhn EW, Liakopoulos OJ, Stange S, et al. Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. Eur J Cardio Thorac Surg 2014;45:17-26; discussion 26
   PubMed Web of Science ®Google Scholar
• Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011;123:1622-32
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(23 Suppl 1):III39-43
   PubMed Web of Science ®Google Scholar
• Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J 2003;145:248-53
   PubMed Web of Science ®Google Scholar
• Karpov IuA, Buza VV. [Prognostic value of markers of inflammation in patients with stable ischemic heart disease after implantation of stents with drug covering at the background of long-term therapy with statins (inhospital period)]. Kardiologiia 2012;52:4-9
   PubMed Web of Science ®Google Scholar
• Karpov Y, Buza VV. Pre-procedure C-reactive protein and erythrocyte sedimentation rate but not lipoprotein-associated phospholipase A2 predict clinical outcomes after drug-eluting stents implantation in patients with stable coronary disease on chronic statin therapy. Circulation 2015;126:A9356
   Google Scholar
• Campeau L. Letter: grading of angina pectoris. Circulation 1976;54:522-3
   PubMed Web of Science ®Google Scholar
• Head SJ, Holmes DR Jr, Mack MJ, et al. Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC Cardiovasc Interv 2012;5:618-25
   PubMed Web of Science ®Google Scholar
• Yao HM, Wan YD, Zhang XJ, et al. Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open 2014;4:e004892
   Google Scholar
• Zahn R, Neumann FJ, Buttner HJ, et al. Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry. Clin Res Cardiol 2012;101:709-16
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;253:281-344
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Marroquin OC, Weissfeld JL, et al. Beneficial effects of statins after percutaneous coronary intervention. Eur J Cardiovasc Prev Rehabil 2009;16:445-50
   PubMedGoogle Scholar
• Boytsov SA, Khomitskaya YV. Centralized PAN-Russian Survey on the undertreatment of hypercholesterolemia (Cepheus). Cardiovasc Ther Prev 2013;12:67-74
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Euroaspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
   PubMed Web of Science ®Google Scholar
• Lee JA, Sunwoo S, Kim YS, et al. Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care. Curr Med Res Opin 2013;29:751-60
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-S45
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6
   PubMed Web of Science ®Google Scholar
• Retterstol L, Eikvar L, Bohn M, et al. C-reactive protein predicts death in patients with previous premature myocardial infarction – a 10 year follow-up study. Atherosclerosis 2002;160:433-40
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528-36
   PubMed Web of Science ®Google Scholar
• Zebrack JS, Muhlestein JB, Horne BD, et al. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002;39:632-7
   PubMed Web of Science ®Google Scholar
• Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7
   PubMed Web of Science ®Google Scholar
• de Winter RJ, Koch KT, van Straalen JP, et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003;115:85-90
   PubMed Web of Science ®Google Scholar
• Oemrawsingh RM, Cheng JM, Akkerhuis KM, et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention 2016;13:345-51
   Web of Science ®Google Scholar
• Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-46
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5
   PubMed Web of Science ®Google Scholar
• Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3
   PubMed Web of Science ®Google Scholar
• Ellis SG, Anwaruddin S. Recapturing the magic: revisiting the pleiotropic effects of statins in percutaneous coronary revascularization. J Am Coll Cardiol 2009;54:566-8
   PubMed Web of Science ®Google Scholar